No Data
Phathom Pharmaceuticals Will Present VOQUEZNA Data At DDW 2024 Annual Meeting, Being Held May 18-21
First oral presentation of Phase 3 data evaluating the investigational use of VOQUEZNA in Non-Erosive Reflux Disease (NERD)1New research on Erosive gastroesophageal reflux disease (GERD) demonstrating
Craig-Hallum Remains a Buy on Phathom Pharmaceuticals (PHAT)
Express News | HC Wainwright & Co. Reiterates Buy on Phathom Pharmaceuticals, Maintains $28 Price Target
Phathom Pharmaceuticals | 10-Q: Quarterly report
Analysts Offer Insights on Healthcare Companies: Phathom Pharmaceuticals (PHAT), ACELYRIN, INC. (SLRN) and Moderna (MRNA)
Phathom Pharmaceuticals, Inc. (PHAT) Reports Q1 Loss, Lags Revenue Estimates